• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Sep. 7, 2023

View Archived Issues
Merger-arrows-black-white.png

Laborie’s continuing M&A labors pay dividends with projected $600M purchase of Urotronic

Laborie Medical Technologies Inc. continued a string of recent deals with an agreement to acquire Urotronic Inc. for $255 million cash up front with an additional $345 million in payments contingent on meeting specified commercial and reimbursement milestones. Laborie already held a minority interest in the manufacturer of the Optilume drug-coated balloon technology for treatment of urethral strictures and benign prostatic hyperplasia (BPH). Read More
Ibexs-Galen-Breast-HER2.jpg

Ibex raises $55M, launches AI product for more accurate HER2 scoring

Ibex Medical Analytics Ltd. closed a $55 million series C financing round that will allow the company to expand its footprint in the U.S. to meet the increasing demand for artificial intelligence (AI)-powered diagnostic solutions. Ibex has developed the Galen platform which offers AI solutions that allow pathologists to accurately and rapidly detect and diagnose cancer. The company also reported the launch of Galen Breast HER2, a new software which will play a critical role in helping oncologists identify effective therapies for breast cancer patients. Read More
Gavel and FTC logo

US FTC and DOJ garner mixed reviews of proposed merger regulation framework

Two U.S. federal government departments recently issued a series of guidelines for their handling of mergers and acquisitions in a draft that has provoked both support and opposition from observers. Barry Nigro of the George Washington University School of Law said he is concerned that the presumption that a transaction is necessarily anticompetitive will prompt litigation over that presumption and thus bog down the process of reviewing these transactions. Read More

White paper delves into US regulatory aspects of AI in drug, device development

While the U.S. FDA’s preclinical and clinical trial framework is generally well-suited to adapt to the use of artificial intelligence (AI) in developing new drugs, its regulatory framework for medical devices that incorporate evolving AI leaves a lot to be desired, according to Sen. Bill Cassidy (R-La.), the ranking member of the Senate Health, Education, Labor and Pension Committee. Read More
Pacira Cryotech cryogenic treatment

Patent update: Pacira Cryotech seek to repurpose its analgesic iovera technology for treating arrhythmia

Pacira Cryotech Inc. reported the filing of a patent for a hand-held cryogenic treatment system with a probe configured to apply a cryogenic therapy to one or more nerves, such as the nerves of the stellate ganglion and autonomic tissue peripheral to the stellate ganglion. Read More

Appointments and advancements for Sept. 7, 2023

New hires and promotions in the med-tech industry, including: Biosero, One Biosciences. Read More

Financings for Sept. 7, 2023

Med-tech firms raising money in public or private financings, including: Veinway. Read More

In the clinic for Sept. 7, 2023

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Ciliatech, Istar Medical, Lucid Diagnostics. Read More

Other news to note for Sept. 7, 2023

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Body Vision, Click, Endologix, Indivior, Mediflex, Paige AI Inc., Profound Medical, Scipher Medicine, Strata Oncology. Read More

Regulatory actions for Sept. 7, 2023

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alveofit, Boston Scientific, Implantica. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • Antibodies

    Abbvie gains rights to IGI’s trispecific ISB-2001 in $1.9B+ deal

    BioWorld
    Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation (IGI) Inc. has signed with Abbvie Inc. a...
  • PTAB hands Exact a loss in Geneoscopy patent dispute

    BioWorld MedTech
    The med tech patent wars opened a new front in the region of screening tests for colorectal cancer, pitting Exact Sciences Corp., of Madison, Wisc., against St....
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe